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Objective: Reports continue to document the occurrence of major adverse events after endovascular aortic aneurysm
repair. Althoughmany of these problems can be successfully managed through endovascular salvage, operative conversion
with explantation of the endoprosthesis remains necessary in some patients. We report herein a review of all patients
initially enrolled in multicenter US clinical trials of the Excluder endograft who underwent secondary conversion to open
surgical repair.
Methods: Clinical data and relevant medical records of patients enrolled in phase I and II multicenter US clinical trials of
the Excluder endograft were retrospectively reviewed for adverse events and further narrowed to those patients who
underwent secondary operative conversion. Hospital records, operative and anesthesia reports, and all imaging studies
were analyzed at initial implantation and at the time of subsequent open surgical repair.
Results: Late open conversion was performed in 16 (2.7%) of the 594 patients enrolled in the Excluder clinical trials.
Presumed endotension accounted for 8 of 16 of secondary conversions. In two of these patients, however, an endoleak
was identified at the time of open surgical repair. Of the remaining eight patients, two underwent conversion for device
infection, five for persistent endoleak, and one for aneurysm rupture. The overall 30-day mortality was 6.25% (1/16),
with one death occurring in a patient with a ruptured aneurysm. Of patients who underwent conversion because of
endotension, the maximal abdominal aortic aneurysm diameter (mean  SD) at the time of initial implantation and
subsequent graft removal was 61  11 mm and 70  10 mm, respectively. The mean time to open conversion for
treatment of endotension was 37  12 months (range, 20-50 months; median, 42 months). Freedom from conversion
was 98.6% and 96.7% at 24 and 48 months, respectively.
Conclusions: Endotension in the absence of a demonstrable endoleak has been a major indication for late surgical
conversion in patients treated with the Excluder endograft. Given the potential presence of an undetected endoleak and
the possible effects of progressive sac enlargement on long-term device stability, continued close surveillance of patients
with assumed endotension is required. Should changes in device design eliminate endotension, a further reduction in the
already low incidence of late open conversion of the Excluder endograft can be anticipated. (J Vasc Surg 2005;42:
631-8.)Endovascular repair has become an accepted modality
for the treatment of abdominal aortic aneurysms (AAAs). It
is significant that two recent prospective, randomized stud-
ies have now demonstrated that this minimally invasive
treatment strategy is associated with a reduction in 30-day
perioperative mortality when compared with an open sur-
gical approach.1,2 Other proven advantages include de-
creased operative blood loss, shorter hospital stays, reduced
use of intensive care units, fewer major postoperative com-
plications, and more rapid convalescence.3,4 Moreover, it is
also noteworthy that primary conversion is increasingly
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doi:10.1016/j.jvs.2005.05.056uncommon because of improvements in endograft and
delivery system design, advances in three-dimensional im-
aging, increasing experience in the selection of anatomically
appropriate patients, and a general enhancement in physi-
cian expertise. Nonetheless, multiple reports continue to
document major adverse events after endovascular aortic
repair, including component separation or migration, loss
of device integrity, endograft infection, limb occlusion, en-
doleak, aneurysm enlargement, and aneurysm rupture.5-11Al-
though many of these problems can be successfully man-
aged through endovascular salvage, operative conversion
with explantation of the device remains necessary in some
patients.12-15
The Excluder (W.L. Gore, Inc, Flagstaff, Ariz) is cur-
rently one of four endografts approved by the US Food and
Drug Administration for clinical use in the treatment of
infrarenal AAA. Analysis of mid-term data has revealed that
the Excluder is associated with a higher aneurysm expan-
sion rate than that observed with other commercially avail-
able devices.16,17 Some of these patients demonstrate an-
eurysm enlargement despite the absence of a visible
endoleak—a phenomenon termed endotension. To date,
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patients after endovascular aneurysm repair ranges from 2%
to 5%.18-21 Certainly, aneurysm shrinkage alone cannot be
considered an absolute indicator of a durable result, be-
cause aortic rupture has been documented during periods
of diminishing sac size.21,22 Nonetheless, considerable de-
bate remains concerning the significance of endotension,
because a reduction in aneurysm diameter or volume con-
tinues to be viewed as a valuable surrogate marker of a
successful clinical outcome. Given recent reports of a rela-
tively high incidence of late sac enlargement in association
with the Excluder endograft,16,17 we undertook a review of
all patients initially enrolled in multicenter US clinical trials
of this device who underwent subsequent secondary surgi-
cal conversion to open repair.
MATERIALS AND METHODS
Excluder endograft. The Excluder endograft, a bifur-
cated endoprosthesis, is composed of two components: a
trunk-ipsilateral endoprosthesis and a contralateral leg en-
doprosthesis. The graft material is expanded polytetrafluo-
roethylene (ePTFE) and fluorinated ethylene propylene
(FEP). Thematerial is supported by nitinol (nickel titanium
alloy) wire along its external surface, which is attached to
the graft by a bonding film rather than by sutures. In the
trunk-ipsilateral component, nitinol anchors and an ePTFE/
FEP sealing cuff are located at the aortic end of the trunk.
Deployment of the endoprosthesis is initiated at the proximal
aortic end of the device and proceeds to the iliac end. The
ePTFE/FEP sleeve remains between the endoprosthesis and
the vessel wall in situ after deployment.
Two slightly different device configurations were used
during the US clinical trials: three modifications were made
over the course of the last trial. The first modification
involved a change in the wire used in the ipsilateral trunk
component of the 28.5-mm device. Specifically, a series of
two separate nitinol wires that had been fused to form circum-
ferential wires were replaced by a series of single continuous
wires. The second modification standardized the angle of the
anchors to 45°. The third modification changed the nomi-
nal width of the sealing cuff from 1.5 to 2.0 cm. This had
the additional effect of moving the sealing cuff 7 mm
proximally on the device.
Methods. All the phase I and II multicenter US clini-
cal trials for the feasibility evaluation of the Excluder were
reviewed (protocols 9702, 9803, 9803CA, 9904, and
9904CA). All clinical data and relevant medical records of
enrolled patients were retrospectively reviewed for adverse
events and further narrowed to those patients who under-
went secondary operative conversion. Hospital records,
operative reports, anesthesia reports, and follow-up evalu-
ation, including imaging studies, were analyzed at the time
of implantation and explantation for patients who under-
went secondary conversion. Intraoperative primary conver-
sions were excluded. Routine follow-up evaluation, which
included contrast-enhanced computed tomography (CT), oc-
curred at 1 or 3 months, 6 months, 12 months, and annually
thereafter. Analyzed factors included demographic informa-tion and medical history, initial aneurysm diameter and diam-
eter at the time of conversion, initial endoleak, time to con-
version, indications for conversion, estimated blood loss,
operative time, intraoperative findings, intrasac pressure, post-
operative course, perioperative complications, and mortality.
Results are expressed as mean  SD (range) for continuous
data and as a percentage for categorical data.
RESULTS
A total of 594 patients were enrolled in the initial Gore
Excluder US clinical trials between January 1998 and
November 2002. Secondary conversion to open repair has
been performed in 2.7% (16/594) of patients enrolled.
This subgroup consisted of 13 men and 3 women. Demo-
graphic characteristics and relevant medical history are
summarized in Table I, as are a comparative set of demo-
graphic features for the entire patient population enrolled
in the phase II clinical trial. Among the patients who
underwent subsequent conversion, the pretreatment maxi-
mum aneurysm diameter was 58  10 mm (range, 45-84
mm; median, 55 mm). The mean time from initial implanta-
tion to surgical conversion was 34 17 months (range, 2-52
months; median, 40 months). At the time of conversion, the
meanmaximum aneurysm diameter was 68 14mm (range,
35-92 mm; median, 67 mm), with a mean interval increase in
AAAdiameter of 99.6mm(range,10 to27mm;median,
9 mm). The reasons for open conversion are categorized in
Table II. Endotension accounted for 50% of secondary
conversions. Of patients who underwent conversion be-
cause of endotension, the mean maximal AAA diameter at
Table I. Demographic characteristics and medical history
Variable Explant subgroup
Phase II US
clinical trials
Mean age, y (range) 75 (62-83) 73.6 (48-92)
Sex (% male) 81% 83%
Coronary artery disease 50% 63%
Peripheral arterial disease 13% 19%
Chronic renal insufficiency 0% 1%
Carotid disease 31% 11%
Pulmonary disease 6% 28%
History of tobacco use 63% 85%
Table II. Reasons for secondary conversion (n  16)
Variable n
Rupture 1
Assumed endotension* 8
Endoleak
Type I 1
Type II 4
Graft infection 2
*Includes two patients in whom endoleak was first detected at the time of
operative conversion.the time of initial implantation and subsequent graft re-
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Volume 42, Number 4 Kong et al 633moval was 61  11 mm (range, 52-84 mm; median,
55.5 mm) and 70  10 mm (range, 60-90 mm; median,
66.5 mm), respectively. The mean time to open conversion
for an initial diagnosis of endotension was 37 12 months
(range, 20-50 months; median, 42 months). Freedom
from conversion was 98.6% and 96.7% at 24 and 48
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Fig 1. Freedom from surgical cmonths, respectively (Fig 1).Only a single aneurysm rupture occurred that subse-
quently underwent surgical conversion and endograft
removal. This resulted from a type I endoleak that had been
diagnosed before aneurysm rupture. The patient was an
elderly woman who was considered at high risk for elective
open surgery because of severe cardiac and pulmonary
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an appropriate endograft candidate. The main body of the
device was displaced 15 mm distally at the time of deploy-
ment. Intraoperative angiography revealed that aortic neck
angulation approached 90° and, in retrospect, that it had
been significantly underestimated. Efforts at endovascular
correction of the type I endoleak were unsuccessful. The
patient had a persistent type I endoleak identified on post-
operative and follow-up CT images. Because of concomi-
tant medical comorbidities, the patient refused elective
surgical conversion. At the time of rupture 40months later,
the aneurysm had expanded to 92 mm. Emergency open
conversion was attempted with aneurysm ligation, en-
dograft exclusion, and placement of an extra-anatomic
bypass. This repair was unsuccessful, and the patient died.
Freedom from conversion for aneurysm rupture in this trial
population was 1.0 and 0.996 at 24 and 48 months, respec-
tively (Fig 2).
Graft infection was the cause of explantation of two
devices. In both cases, aortoduodenal fistulas were identi-
fied at the time of operation. In one case, the patient
presented 2 months after the initial implantation complain-
ing of back pain, fevers, and chills. Staphylococcus aureus
grew on blood cultures, and CT imaging revealed a peri-
graft fluid collection consistent with a graft infection. The
patient underwent a staged intervention with an initial
axillobifemoral bypass followed 4 days later with excision of
the infected device and repair of the fistula. The patient was
discharged 19 days after open surgical repair on long-term
intravenous antibiotics. The second case occurred 49 months
after initial implantation. One month before hospitalization,
follow-up evaluation revealed that aneurysm size was un-
changed as compared with the dimensions measured at the
initial repair. The patient subsequently complained of fevers
and rigors, and a CT scan revealed gas within the aneurysm
sac. Blood cultures identified both fusobacteria and pep-
tostreptococci. The patient underwent a staged interven-
tion with an initial axillobifemoral bypass followed 2 days
later by graft excision. A prolonged postoperative course
ensued with multiple complications. The patient was dis-
charged on postoperative day 51 to a skilled nursing facility
but aspirated and died on postoperative day 71.
Five explants were electively performed as a result of an
initial diagnosis of endoleak. In one instance, the infrarenal
aortic aneurysm progressively enlarged to involve the mes-
enteric vessels. Three months after endovascular repair, the
proximal attachment site was no longer approximated against
the aortic wall, and surgical conversion was performed 1
month later. The other four explants were a consequence of
persistent type II endoleaks combined with sac expansion.
Comparison of operative variables is found in Table III. On
exploration, two endoleaks originated from retrograde
lumbar arterial flow, one endoleak resulted from retrograde
inferior mesenteric arterial and lumbar arterial flow, and
one subject had no identifiable endoleak.
The remaining eight explants (50%) were initially at-
tributed to the presence of endotension. Intraoperative
analysis at explantation revealed that two patients had anunrecognized type II endoleak from patent lumbar arteries.
Both of these patients had been followed up with routine
CT imaging. One patient had an arteriogram soon after
endograft implantation, without visualization of an en-
doleak. However, over the course of 44 months, the aneu-
rysm gradually enlarged from 56 to 66 mm. In the second
patient, an arteriogram was performed 12 months after the
initial repair to evaluate an aneurysm that had expanded
from 52 to 60 mm. Surgical conversion was performed 6
months later. On exploration of the other six patients, a
highly viscous or gelatinous material was discovered when
the sac was entered. Sac pressures were obtained at explan-
tation in six of these patients. Among five of these patients,
the mean arterial blood pressure was 58.0  23.6 mm Hg
(range, 17-75 mm Hg). In the remaining patient, the sac
pressure was noted as equivalent to the arterial blood
pressure, but a value was not recorded at the time of
exploration. Although in one patient the sac mean arterial
blood pressure was 17 mm Hg, patent lumbar artery with
retrograde arterial flow was noted when the aneurysm was
opened.
Structural analysis was performed on all explanted de-
vices. This revealed a single wire fracture in one device.
Fabric disruption or microleaks were not detected in any
explanted device. The overall 30-day mortality was 6.25%.
One death occurred in a patient with a ruptured aneurysm.
DISCUSSION
The Excluder endograft has proven to be an innovative
device for the treatment of patients with AAA. High tech-
nical success rates and promising early and mid-term clinical
outcomes have been observed in a series of clinical reports
describing the results of Food and Drug Administration–
approved clinical trials, national and multinational regis-
tries, and single-institutional experiences.17,23 However,
surgical explantation of Excluder endografts has been re-
quired, as has been the case for all endovascular grafts. As
noted in our review, freedom from conversion was 98.6%
and 96.7% at 24 and 48 months, respectively. These are
similar to the conversion rates previously reported from
other multicenter multidevice registries.24,25 In a review of
device-specific outcomes at the Cleveland Clinic, Ouriel
et al20 reported a 1.7% incidence of secondary conversion
that did not differ significantly among devices. Likewise,
these authors have also reported that freedom from second-
ary procedures was similar among Ancure (Guidant, Inc.,
Indianapolis, IN), AneuRx (Medtronic, Minneapolis,
MN), Excluder, Talent (Medtronic, Minneapolis, MN),
and Zenith (Cook, Bloomington, IN) aortic endografts.26
Notably, our review bears out the infrequent occurrence of
Excluder endograft migration, limb dislocation and ob-
struction, and wire fracture or fabric disruption as a cause of
endoprosthesis failure. Among patients enrolled in the US
clinical trials, none of these events led to late operative
conversion. In addition, conversion due to aneurysm rup-
ture in our study population was rare, with a calculated
freedom from conversion of 1.0 and 0.996 at 24 and 48
months, respectively. This risk seems comparable to that
JOURNAL OF VASCULAR SURGERY
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database, which reported an overall freedom from rupture
of 98.6% at 4 years.27Overall, persistent endoleak or device
infection was a primary cause for surgical conversion, as has
been the case for most other devices. However, in contra-
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Fig 2. Freedom from surgical conversion of thdistinction to other endoprostheses, endotension has beena much more common indication for explantation of the
Excluder endograft.
Endotension refers to the enlargement of an aneurysm
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W.L. Gore, aneurysm enlargement was defined as a diam-
eter expansion of 5 mm or more. In the absence of an
identifiable endoleak, the origin of endotension-related sac
expansion remains somewhat obscure, although some have
suggested that transgraft plasma filtration or a missed or
sealed endoleak may be the cause.28-30 Indeed, Thoo et
al31 have recently reported the occurrence in five patients of
a symptomatic perigraft seroma within the aortic sac after
open repair of an AAA with a ePTFE graft. All patients
presented with abdominal or back pain. In one instance,
there was a retroperitoneal hematoma due to disruption of
the perigraft sac wall.
As reported herein, 2 of 8 cases of aneurysm sac en-
largement that had been presumptively labeled as endoten-
sion related were found to harbor a previously undetected
endoleak. The remaining six patients had aneurysm sacs
that contained a serous, exudative material. It is significant
that these data highlight that despite rigorous preoperative
assessment, a portion of patients with conditions initially
diagnosed as endotension may have an unrecognized en-
doleak. Several investigators have argued that a type II
endoleak does not substantially increase the risk of aneu-
rysm rupture.21,22,32 Nevertheless, aneurysm rupture as a
result of a persistent type II endoleak has been well docu-
mented.22,24 Further, although recent reports have sug-
gested that certain features of type II endoleak, such as
increased size and flow rate, may identify patients at in-
creased risk of aneurysm enlargement, the capacity to dis-
cern patients at greater or lesser risk of rupture remains
difficult.
An interim update of the pivotal clinical trial data for
the Excluder endograft now suggests that the incidence of
endotension, as defined by an increase in sac diameter of 5
mm or more, may approach 33% 4 years after endovascular
aneurysm repair.17 Although the current commercial ver-
Table III. Secondary conversions*
Variable All secondary conversions
Initial aneurysm size (mm) 58.4  9.7 (45-84)
Final aneurysm size (mm) 67.7  14.1 (35-92)
Interval aneurysm increase
(mm) 8.9  9.6 (10 to 27)
Time to conversion (mo) 33.7  16.8 (2-52)
Explant operative time
(min) 230.3  85.2 (128-390)
Explant EBL (mL) 2395.0  2121.6 (600-8000)
Sac MAP (mm Hg) 64.4  21.1 (17-83) 8 patients
Length of ICU stay (d) 6.4  14.3 (0-51)
Length of hospital stay (d) 11.2  12.6 (3-51)
Data are mean  SD (range).
EBL, Estimated blood loss; MAP, mean arterial blood pressure; ICU, inten
*No statistical significance between any groups.
†Includes two patients in whom endoleak was first detected at the time of osion of the Excluder endograft has been redesigned with alow-porosity fabric to reduce the potential of transgraft
filtration and address this concern, the positive effect of this
strategy has not yet been confirmed. To date, there have
been no reported cases of endotension-related aortic aneu-
rysm rupture in the United States or abroad for the Ex-
cluder endograft implanted either in a clinical trial or post-
market setting. Indeed, in our review, only one aortic
rupture (a result of a previously diagnosed type I endoleak
for which the patient had refused treatment) was identified
among clinical trial patients treated with the Excluder
endograft.
In our analysis, the proportion of patients who un-
derwent surgical conversion represents a small subset of
those enrolled in the Excluder clinical trial with assumed
endotension. Indeed, absolute indications for conver-
sion in the otherwise asymptomatic patient have not
been established, and several alternate treatment options
have been suggested for the management of endoten-
sion, including translumbar aspiration of sac contents
and open or laparoscopic fenestration of the aneurysm
wall to facilitate intraperitoneal drainage of sac fluid.
Some have also suggested that, where feasible, place-
ment of a second less porous endograft within the orig-
inal device may provide a means to promote aneurysm
shrinkage. Alternatively, Lipsitz et al14 have reported the
treatment of endotension by wrapping a standard tube
graft over an operatively exposed endograft. In many
cases, continued surveillance may be the most suitable
course of management. However, it bears emphasis that
thorough imaging by CT, ultrasonography, and multi-
view selective angiography is mandatory in all of these
patients to minimize the risk of failing to detect an
endoleak. We believe that it is appropriate to counsel
patients that the absolute risk of an endotension-related
adverse event remains low. However, should a program
of surveillance be pursued, close lifelong follow-up is
onversions due to endoleak
(n  5)
Conversions due to assumed
endotension† (n  8)
5.4  9.8 (45-70) 60.9  10.9 (52-84)
2.0  15.7 (35-75) 70.2  10.2 (60-90)
6.6  10.6 (10 to 19) 9.4  7.1 (4 to 22)
0.2  21.6 (4-52) 37.1  11.6 (20-50)
0.0  77.8 (192-372) 213.3  90.2 (128-390)
0.0  3265.0 (1000-8000) 1992.5  1396.1 (600-4440)
75  13 (60-83) 3 patients 58.0  23.6 (17-75) 5 patients
3.4  4.0 (0-10) 1.5  0.5 (1-2)
0.0  5.6 (7-20) 6.3  1.7 (3-8)
re unit.
ve conversion.C
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6
3
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peratimandatory. At present, the natural history of endoten-
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continued aneurysm enlargement could lead to either a
loss of device fixation and endograft migration or a late
endoleak. All of these events may result in frank aneu-
rysm rupture.
In our analysis, explantation of the Excluder endograft
was associated with a 6.25% 30-day mortality; one death
occurred in a patient with a ruptured aneurysm. In this
regard, several recent reports have described in detail oper-
ative strategies directed at minimizing the morbidity and
mortality of secondary conversion, including suprarenal
control or use of iced saline to facilitate barb extraction of
nitinol-based devices. Nevertheless, operative mortality
with secondary endograft conversion has ranged up to 32%
and averaged 22% in a recent compilation of reported
series.12 Of note, in the series reported herein, open con-
version for endotension was not associated with periopera-
tive mortality. Overall, given the inability to exclude an
undetected endoleak with complete certainty, consider-
ation of surgical conversion may be prudent for patients
with continued sac expansion who are otherwise excellent
surgical candidates.
CONCLUSIONS
Endotension in the absence of a demonstrable en-
doleak has been the primary indication for late surgical
conversion in patients treated with the Excluder endograft.
Although it is reassuring that aortic rupture or endograft
malfunction has not been reported secondary to endotension,
the need for additional imaging studies, the potential of an
undetected endoleak, and the possible effects on long-term
device stability must be acknowledged as current device limi-
tations. Although the present version of the Excluder en-
dograft has been redesigned with a low-porosity fabric to
address this concern, a reduction in the incidence of endoten-
sion has not yet been confirmed. Thus, continued close sur-
veillance of these patients is required.
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